Müller et al. investigated the relevance of miR-21, miR-210, and miR-373 in the serum of 127 HER2+ BC patients before and after chemotherapy combined with either trastuzumab or lapatinib treatment as well as compared to 19 healthy controls [153]. This evidence concerns the gene ERBB2 and breast cancer.